Story Of P1P :: '피토페시아' 태그의 글 목록

피토페시아 스칼프 에센스

PHYTOPECIA Scalp Essence


피토페시아 스칼프에센스는 이런 분에게 좋습니다. 

- 펌,염색"을 하셨으면 "P1P스칼프에센스"가 필수!!

- '두피염증 및 가려움증 회복에 탁월

- 모낭이식 수술 후 두피회복(모발 생착율 증가) 


[효능효과] 

-  염색(탈색) 또는 펌 용제에 노출된 두피를 진정시켜주고 빠른시간내에 정상적인 두피로 회복시켜, 두피 노화를 방지하고 건강한 모발유지에 도움을 줍니다.

- 염색 후 1회 사용만으로도 두피 진정 및 회복 효과가 나타나며 가려움증을 완화합니다. (증상이 중증인 분은 4-7일간 꾸준히 사용 하시면 좋습니다.

- 모발이식 후 사용하면 상처회복, 진정효과 및 모발의 생착율을 높이는데 도움을 줍니다.

- 무방부제 제형으로 피부 알러지 최소화


[효능성분] 

-  P1P /피토스핑고신포스페이트

소판에서 분비하는 스트레스 해소 및 상처치유 물질인 S1P유사체로  염색 및   으로 인한 두피 스트레스를 개선하여 모낭세포가 죽는 것을 막아주고 두피에 새로운  모세혈관생성을 촉진시켜 탈모예방 및 치료에 도움을 .

- Centella Asiatica Extract/병풀잎 추출물

센텔라 아시아티카 추출물, 마데카솔 연고의 원료이며 아토피에 효과적이며 콜라겐합성촉진으로 모공 축소와 탄력을 증가시키는 능력이 탁월하며 외부로부터 유해물질의 침투를 방지하고 상처치유혈액순환 촉진.

-  D-Panthenol/판테놀

상피세포 생성 촉진상처 치유 도움항염효과가려움증 완화

-  Paeonia Suffruticosa Root Extract/모란뿌리추출물

모란뿌리추출물, 피부트러블 및 탄력저하 예방에 효과적이며 해열, 진통, 소염작용 및 가려움증 완화.

-  Green Tea/녹차잎 추출물

항산화제 다량 햠유 및 탈모원인 호르몬 일종인 DHT 생성을 억제하여 탈모방지



2액형 염모제의 산화제에 의한 세포 손상과 회복

P1P염색시 사용되는 산화제(산화적인 스트레스)에 의해 감소된 두피 섬유아세포의 콜라겐 합성 능력을 빠르게 회복시킴.

염색시 사용하는 산화제를 처리하면 세포가 죽어가지만,

 P1P(100nM)을 처리하면 세포가 염색 이전의 상태로 회복 됨


과산화수소(산화제)에 노출된 섬유아세포의  콜라겐 합성량이 현저히 감소함.

 P1P를 처리하면 콜라겐 합성 능력이 원상 회복될 뿐 아니라 

높은 농도에서는 처리 전보다 많은 양의 콜라겐 합성이 이루어짐. 

활성산소 등 산화제에 의한 피부노화를 억제 함.


P1P의 농도가 증가함에 따라 콜라겐을 만드는 mRNA의 양이 현저히 증가함.

 2.5μg/mlL의 낮은 농도에서도 약 3.5배 증가 함.

Induction of hair growth by phytosphingosine-1-phosphate (P1P) in C3H/HeJ mice model





P1P (0.01%)를 피부에 도포하면 모발성장이 촉진되는 것을 발표하였으며, Minoxidil과 유사한 정도로 hair growth가 일어나며, minoxidil angen (성장기)에서 catagen (퇴행기)으로 많이 진행되며, P1P telogen (휴지기)에서 anagen (성장기)으로 전환되는 양상을 보이며, P1P hair growth 기전으로 B-Catenin  Wnt 단백질의 발현을 증가시킴따라서 P-1-P는 탈모치료에 유용하게 사용할 수 있는 물질임.



2012, 유럽피부모발학회 발표 -PMK-

[발표자료:https://docs.google.com/file/d/0B1fk2h65xEgATlpWWmtuQ2NCWFk/edit?usp=sharing]


Molecular principles of hair follicle induction and morphogenesis


모낭 형성에 중용한 역할을 하는 단백질은 B-Catenin Wnt 단백질임. Wnt 단백질은 모발의 발생과 성장에 관여하는 신호전달 단백질임. Wnt 신호전달이 없으면 epidermal cell fate로 가지만, Wnt 신호전달이 활성화되면 hair follicle fate로 감. Wnt에 의한 신호전달이 B-Catenin으로 이어져 모낭형성이 이루어짐. 따라서 B-Catenin Wnt 단백질의 형성이 탈모치료에 중요한 역할을 담당함.



Our present working hypothesis, for induction of primary (guard; A) and secondary (non-guard, awl; B and C) pelage hair follicles. A: On the left side, the different stages of early hair follicle development are depicted (stage 0–5), according to the original hypothesis of M. Hardy.(6) In mammals, it is not yet known how inductive fields are created prior to initiation of hair follicle placode formation. Thus, the question mark above stage 0. To the right the currently known activation pathways involved in primary guard hair development are shown. Essential inducers are Wnt and EdaA1/EdaR/NF-kB. B: Secondary hair induction calls for Wnt and Noggin. A model concerning inhibition of BMP4 in the dermal papilla and BMP2 in the ectoderm by BMP anatgonist Noggin was proposed by Botchkarev et al.(24) Localized Noggin expression in the dermal papilla antagonizes the potent placode-growth-inhibitory action of the two BMPs and leads to Lef-1 expression. Noggin also inhibits p75NTR expression, which functions as a receptor that negatively regulates hair follicle growth.(94) Jamora et al. go a step further in proposing that Noggin is directly responsible for activation of uclear Lef-1 expression in secondary hair follicles.(33) They suggest that Noggin must counteract any BMP action in the developing follicle because BMP is the key inhibitor of Lef-1 expression. Figure adapted from Botchkarev et al.(24) C: Scheme of the currently known signaling pathways involved in secondary awl hair induction. As shown in B, apart from Wnt signaling, Noggin is the second essential inducer. The numbers (1.–3.) indicate the possible order of events occuring to initiate awl hair development. One major difference of primary guard hairs compared to secondary awl hairs is the EdaA1/EdaR/NF-kB pathway, only activated during initiation of guard hairs. Inhibition of any component of this pathway leads to absence of guard hairs.(22,23) Wnt in both pathways stands for any Wnt, the exact one being unknown. The best-defined so-alled ‘‘inhibitors’’ of hair follicle development, Dkk1 and BMPs, are boxed and marked in black. Dkk1 is a true inhibitor and, ectopically expressed in the ectoderm,it prevents formation of all hair follicle types by complete inhibition of Wnt signaling.(30) However, BMPs do not have a clear inhibitory role. They are in part activators and inhibitors, depending on the developmental stage. BMPs are expressed from early on in both hair types, and at least in secondaryHFstheyseemto be needed for active b-catenin complexes and downstream target gene expression of Wnt/b-catenin/Lef-1.(110,111) The exact role of BMPs in early guard hair follicles remains unknown. However, BMP action may have to be anatgonized by Noggin at later stages of guard hair follicle morphogenesis.(25,112) Shh/Gli2 signaling is activated at a later time point at stage 2–3(hair germ—peg), and is only to a minor degree responsible for dermal papilla formation of both hair types, but seems to be required for dermal Wnt5a expression.(29) Shh/Gli2 is mostly essential for further epidermal downgrowth of the germ and the subsequent peg formation.(12) The formation of secondary zigzag hairs remains to be studied in detail. They seem to demand EdaA1/EdaR/NF-kB signaling later than in guard hairs and further downstream of Wnt/b-catenin and Noggin/Lef-1. Importantly, note that the arrows do not necessarily mean that the protein is directly regulated by a particular pathway, with the exception of Wnt/b-catenin, Eda/NF-kB and Shh/Gli2. In most cases, it means that the indicated protein is activated temporarily downstream. The multiple question marks already imply that there are still many processes that are currently unknown and need to be investigated in the future.


2005, BioEssays

[논문참조:https://docs.google.com/file/d/0B1fk2h65xEgAOVhFbjl2UVlkelk/edit?usp=sharing]


wnt-b-catanin.pdf


B-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin

 

B-Catenin Wnt/wingless 신호전달에 중요한 단백질이며, 배아발생에서 결정적인 단계를 조절하는 단백질임. 또한 모낭의 형성에 중요한 역할을 하는 단백질임. B-Catenin에 돌연변이가

일어나면, 배아발생에서 모낭형성이 억제됨. 모낭이 형성된 후에 B-Catenin이 제거되면, 첫 번째 hair cycle 후에 hair가 완전히 없어짐. 또한 B-Catenin은 모낭 속에 있는 (벌지에 있는) 줄기세포의 운명을 결정하는 단백질임. B-Catenin이 존재하면 줄기세포가 모모세포로 분화가 되지만, B-Catenin이 없으면 줄기세포가 모모세포가 되지 못하고 피부세포로 분화가 됨. 따라서 B-Catenin은 줄기세포가 모모세포로 분화하는 운명을 결정하는 단백질임. 따라서 B-Catenin 단백질의 양을 증가시키는 물질을 탈모치료에 유용하게 사용됨.


Scheme of the Possible Roles of b-Catenin in Hair Follicle Morphogenesis and Skin Stem Cell Differentiation

(a) The genetic placement of b-catenin in the ordered interplay of various signaling pathways mediated by FGF, Downless, BMP, and SHH is shown.

(b) The putative role of b-catenin in the fate decision of stem cells of the bulge between the follicular or epidermal keratinocyte lineages is shown. Modified from Fuchs and Segre, 2000 and Taylor et al., 2000.


2001, Cell

[논문참조:https://docs.google.com/file/d/0B1fk2h65xEgAeHFjd0M3THBVVTg/edit?usp=sharing]


cell 105 533 545 2001.pdf


CRF receptor antagonist Astressin-B reverses and [revents alopecia in CRF over-expressing mice

 

Corticotrophin-releasing factor (CRF) 신호전달 경로는 스트레스 반응에 관여하며, 스트레스에 노출되면 모낭에서 hair growth의 억제가 일어나는 증거들이 많이 있음. Corticotrophin은 스트레스에 의해 분비되는 호르몬임. CRF receptor를 차단하는 물질 (스트레스 억제 물질) hair growth에 어떤 영향을 주는지 조사하였다. Astressin B CRF1 CRF2를 차단하는 물질 (스트레스 억제물질)로 피하주사나 복강주사를 할 경우 탈모를 회복시킨다고 보고함. 또한 이 물질을 피하주사하면 탈모로 발달하지 않도록 예방하는 작용도 함.


Figure 1. The CRF1/CRF2 receptor antagonist, astressin-B, injected intraperitoneally (ip) in CRF-OE mice with fully developed alopecia induces hair growth and pigmentation. Photographs: Row A: Male CRF-OE mice (4 months old) injected ip once daily for 5 consecutive days with saline at 3 days after the last injection and Row B: astressin-B (5 mg/mouse) at 3 days after the last ip injection, and Row C: the

same mice as in the middle panel Row B at 4 weeks after the last ip injection.

doi:10.1371/journal.pone.0016377.g001



2011, PlosOne

[논문참조:https://docs.google.com/file/d/0B1fk2h65xEgAcGFzSTJ1cXpYUzA/edit?usp=sharing]


astresinB.pdf



Substance P as an immunomodulatory neuropeptide in a mouse model for autoimmune hair loss (Alopecia Areata)

Alopecia areata (원형탈모) hair follicle의 자가면역질환으로 substance P가 중요한 역할을 수행함. 원형탈모의 초기상태에서 substance P에 반응하는 신경섬유의 수가 증가하고, 원형탈모가 진행된 경우에는 substance P에 반응하는 신경섬유가 감소하며, substance P를 분해하는 효소 (neutral endopeptidase)가 증가한다. Substance P hair follicle regression을 촉진하고, 비만세포의 탈 과립을 촉진하여 염증반응을 야기함. Substance P를 피부에 도포할 경우 비만세포의 탈과립이 증가하고 hair follicle regression을 촉진함. 이외에 활성화된 CD8+ Tcell을 증가시켜 면역세포가 모낭을 공격하게 함. 스트레스는 substance P를 생성하게하고, 이 물질이 원형탈모를 유도하는 좋은 증거가 됨.


2007, Jouranal Investigative Dermatology

[논문참조:https://docs.google.com/file/d/0B1fk2h65xEgASVRCbjNnNjdRTHM/edit?usp=sharing]


SP-autoimmune hair loss.pdf


Probing the effects of stress mediators on the human hair follicle : Substance P holds central position



스트레스는 hair growth를 변경시키는데, substance P nerve growth factor (NGF)가 중요한 역할을 수행함. Substance P는 스트레스에 연관된 neuropeptide (신경전달 펩티드)로 이 논문에서는 substance P가 모발성장에 어떤 영향을 미치는지 조사함. Substance P hair shaft elongation을 억제하고, 미성숙 catagen 발달을 촉진함. Substance P는 비만세포 (mast cell)의 탈 과립을 촉진하여 염증반응을 촉진하고, NGF 생성 촉진과 세포사멸을 유도함. 따라서 스트레스는 substance P를 만들어, 세포성장을 억제하고, 염증반을을 야기하며, 세포사멸을 촉진해 모발성장를 억제함. 스트레스가 탈모의 원인임을 밝히고 있음.

스트레스에 의해 세포가 사멸되는 것을 억제하기 위해 혈소판에서는 S1P(P1P)를 분비 함.


 2007, American Journal Pathology

[참조논문:https://docs.google.com/file/d/0B1fk2h65xEgAQWhZb2RjMENFUlU/edit?usp=sharing]


stress-human follicle.pdf


P1P 와 S1P 의 구조 및 작용

P1P 연구논문/P1P연구 배경 2013.02.04 15:29 Posted by 최명준박사의 P1P이야기 phytoLife

P1P 와 S1P 의 구조 및 작용



피부상처나 스트레스를 받으면 이를 극복하기 위해 혈소판을 통해 분비하는 자가재생유도 물질인 Sphingosine-1-phosphate (S1P)세포이동, 세포사멸 억제, 신생혈관생성, 상처치유 등을 담당하는 지질 신호전달물질임. S1P는 세포 표면의 receptor에 작용해서 다양한 반응을 일으킴.

S1P receptor 5 종류 (S1P1, S1P2, S1P3, S1P4, S1P5)가 알려져 있음. S1P의 구조 유사체인 phytosphingosine-1-phosphate (P1P) S1P와 같은 receptor에 결합해 세포 내에서 같은 기능을 수행함. P1P S1P1 S1P4에 대해 S1P보다 더 잘 결합하는 special agonist

따라서 P1P도 S1P와 동일하게 세포이동, 세포사멸 억제, 신생혈관생성, 상처치유 등의 작용을 나타냄

최명준 박사 주요이력 및 연구실적

최명준박사 스토리/최명준 Profile 2013.01.22 19:32 Posted by 최명준박사의 P1P이야기 phytoLife

주요이력 및 연구실적

1) 성 명 : 최 명 준 (약사면허번호 제 30765)

2) 소속 및 직책 : (주) 피토스 대표이사


Edcational Background:

B. S.   in Department  of  Pharmaceutics, College  of Pharmacy,Pusan Univ.(1986), 약사면허 소지 (30765)

M. S.  in Department of  Biological Science, Korea Advanced Institute of Science and Technology  (KAIST) (1989)

Ph. D. in Department  of  Life Science  (Biological Science),  Korea Advanced Institute of Science  and Technology (KAIST) (1992)


Dissertation Titles:

M.  S.  Studies in the Formation and Properties of Polymeric Phospholipid

Ph. D.  Formation and Physicochemical Properties of Polymeric pH-Sensitive Liposomes


 Professional Experience:

-  Research and Teaching Assistant, Department of Biological Science, Korea Advanced Institute of Science Technology (1989 - 1992)

-  Project Researcher, Supported by the Ministry of Science and Technology (1987 - 1989)

-  Post Doc. fellowship, in Department of Life Science, Korea Advanced Institute of Science and Technology (1992 - 1993)

-  993-1995.12: 목암연구소 선임연구원

-  996-2001. 7: 목암연구소 책임연구원

-  2001-2002: 유전자 치료제  생물학적 제제 중앙약사심의 위원

-  2001.7-2001. 12: 두산기술원 객원 연구원

-  2001. 12-2005.2: 참존 생물소재연구소 수석연구원

-  2002. 3-2005.2: UCSF 피부과 객원 연구원

-  2005. 3- 2007. 7: 참존 생물소재연구소장

-  2006-present: 피부장벽학회 간행이사

-  2006-present: 산업자원부 생물의약품 생물화장품 기획 위원

-  2007. 7-2010. 8: 한국임상시험센터 센터장

-  2010. 5.-현재: 피토스 대표이사

-  2010. 10-현재: 글로벌코스메틱사업단 평가 자문위원


       Performed and Present Projects:

 1. Development of liposomes system targeted to cancer cells in vitro and in vivo (1991-1993)

 2. Development of targeting system to liver cells using galactose exposed liposomes (1993-1995)

 3. Development of Gag-ENV chimeric protein based HIV vaccine (1994-1996)

 4. Development of V3 peptide based HIV vaccine (1995-1997)

 5. Synthesis of PC containing myristic acid analogs for HIV therapy (1994-1995)

6. Development of liposomal adjuvant for cytotoxic T lymphocytes (CTL) in vivo (1994-1998)

7. Development of CTL based tumor vaccine (1997-1999)

8. Synthesis of New cationic lipids and development of gene therapy for liver cancer (1999-2001)

9. Stabilization of recombinant G-CSF protein with liposomes systems (2000-2001)

10. Preparation and development of liposomes system containing of high content phytosphingosine (2001. 6-2001.12, at Doosan Biotech)

11. Preparation and development of liposomes system containing of high content ceramide and N-acetyl phytosphingosine (2001. 6-2001.12, at Doosan Biotech)

12. In vitro skin penetration of caffeine formulation using human skin (2002, in UCSF)

13. In vivo skin permeation of liposomal methyl nicotinate cream (2002, in UCSF)

14. Antioxidant capacity test of cosmetic creams (2002, in UCSF)

15. Chemical induced protein secretion assay using callus method (2002, in UCSF)

NF-kB decoy (oligonucleotide) formulation and skin permeation assay (2003, finished in UCSF)

16. Evaluation of skin enhancers and retardants on the skin penetration (2004, in UCSF)

17. 나노입자를 이용한 경피흡수 촉진 시스템 개발 피부의약품으로의 적용 (2005-2006, 참존)

18. 항암약물 피부 전달을 통한 국소 건선치료제 개발 (2005-2011, 서울시 전략혁신 클러스터 사업)

19. 항암 T 세포 활성 억제제를 이용한 국소 건선 치료제 개발 (2005, 참존)

20. 면역조절을 통한 아토피 개선 원료의 탐색 (2005, 참존)

21. 면역조절을 통한 자극완화 물질의 개발 (2006, 참존)

22. 발효를 통한 고기능성 식품 의약품 소재  개발 (2005-2006, 참존)

23. 면역조절물질 함유 나노입자를 이용한 아토피 개선 치료제 개발 (2006-2009, 과기부 차세대성장동력 면역기능제어기술개발과제): 바이아토 아토킹 제품 판매

24. EGF 피부투과 촉진 제제 개발을 통한 화장품 개발 상처치료제 개발 (2006-2007, 참존 넥스젠)

25. 스트레스 해소, 신생혈관생성 촉진 물질을 이용한 탈모 예방 치료제 개발 (2007-2010, 피토스): 피토페시아 헤어부스팅 샴푸 피토페시아 헤어토닉 시판

26. 면역증강메비좀을 이용한 항암약물 전달체 개발 완료 


       Interesting Fields (현재 진행 향후 연구 관심분야)

-   나노 입자를 이용한 생리활성 물질의 피부투과 촉진 시스템 개발 피부의약품으로 적용: 생리활성 원료의 피부투과 촉진을 통해 효능 증진 부작용 감소의 개량 신약 개발

-     Bioadhesive film (patch and gel) 이용한 피부 투과형 의약품 개발

-     메비좀을 이용한 항암약물 전달 시스템 개발 국소 건선 치료제의 개발

-     피부면역질환 (아토피, 건선) 개선 치료제 개발

-     상처치유 소재 (EGF, small molecules) 개발 피부투과 촉진 제제화 연구

-     발모 육모 소재 개발 제제화 연구

-     면역증강 메비좀을 이용한 항암약물 전달체 적용


       Publications :

1.   U.H. Kim, E.S. Kim, M.J. Choi, and H. Kim. “Effect of surfactants on the stability of phosphatidylcholine vesicles” Korean J. Biochem. 24, 1-6, (1992)

2.   M.J. Choi, H.S. Han and H. Kim. "pH-sensitive liposomes containing polymerized phosphatidyl -ethanolamine and fatty acids" J. Biochem. 112, 694-699, (1992).

3.   M.J. Choi*, H.S. Cheong and H.M. Moon. "Structure and function of Liposomes" Saenghak nyusu 14(5), 265-272, (1994). * Corresponding author

4.   S.Y. Hong, J.E. Oh, M.J. Choi, J.H. Lee, B.K. Lee, H.M. Moon, K.H. Lee. “Identification and Characterization of Novel Antimicrobial Decapeptides Generated by Combinatorial Chemistry” Antimicrob. Agents Chemother.42(10) 2534-2541 (1998)

5.   L. Luo, Y. Li, J.S. Chang, T.Y. Kim, M.Y. Choi, H.S. Cheong, H. H. Kim, H. J. Ahn, M.K. Min, S.Y. Park, and C.Y. Kang. “Induction of V3-Specific Cytotoxic T lymphocytes Responses by HIV gag Particles Carrying Multiple Immunodominant V3 Epitopes of gp120” Virology 240, 316-325 (1998)

6.   J.S. Chang, M.J. Choi*, T.Y. Kim, S.Y. Cho, and H.S. Cheong. “Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes” Vaccine 17, 1540-1548 (1999) * Corresponding author

7.   J.S. Chang, M.J. Choi*, T.Y. Kim, G.J. Woo, S.I. Chung and H.S. Cheong. “Effect of Dehydration and Rehydration of the pH-Sensitive Liposomes Containing Chimeric gag-V3 Virus Like Particles on their Long-term Stability” Biotechnol. Bioprocess Eng. 4, 66-71 (1999) * Corresponding author

8.   J.S. Chang, M.J. Choi, H.S. Cheong and Kilhyoun Kim. “Development of Th1 mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes” Vaccine, 2001, 19(27) 3608-3614.

9.   W.B. Park, H.K. Cheong, M.J. Choi. “Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis” Cancer Biotherapy & Radiopharmaceuticals, 2001, 16: 439-447.

10.  S. Bian, J. Zheng, M.J. Choi, and D.D. Kim. “In vitro and In vivo studies of topical delivery system of genetisic acid in hairless mice” J. Kor. Pharm. Sci., 2002, 32: 161-164.

11.  M.J. Choi and J.S. Chang. “PH-sensitive liposomes as adjuvants for peptide antigens” Methods in Enzmology, 2003, 373: 127-136.

12.  H. Zhai, M.J. Choi, M. Arens-Corell, B.A. Neudecker, and H.I Maibach. “A rapid, acurate, and facile method to quantify the antioxidantive capacity of topical formualtions” Skin Research and Technology, 2003; 9:1-3.

13.  M.J. Choi and H.I Maibach. “Topical vaccination of DNA antigens: topical delivery of DNA antigens” Skin Pharmacol Appl Skin Phaysiol, 2003; 16 (5): 271-282.

14.  M.J. Choi and H.I. Maibach. “Effect of tape stripping on percutaneous penetration and topical vaccination” Exogenous Dermatology, 2003, 2: 262-269.

15.  M.J. Choi and H.I. Maibach. “Role of ceramides in skin stress: Ultraviolet light, tape stripping and crowding” Exogenous Dermatology, 2003, 2: 286-294.

16.  M.J. Choi, S.H. Kang, S. Kim, H. Cho, J.S. Chang, S.S. Kim and K.H. Lee “The interaction of an antimicrobial decapeptide with phospholipid vesicles”, Peptides, 2004, 25: 675-683.

17.  S.H. Oh, S.H. Kim, M.J. Choi, K.M. Kim and K.N. Kim. “The antibacterial effect of oral rinses containing phytosphingosine against oral microorganisms” The Journal of the Korea Research Society for Dental Materials, 2005, 32(4):  351-357

18.  MJ Choi and HI Maibach “Ceramides in barrier function of healthy and diseased skin” Am J Clin Dermatol, 2005, 6: 215-223.

19.  MJ Choi and HI Maibach “Ceramides in skin stress-Ultraviolet, Tape stripping, and Crowding” Cosmetics & Toiletries, 2005, 120: 46-52.

20.  H Zhai, S Behnam, MJ Choi and HI Maibach “Evaluation of the antioxidant capacity and preventive effects of a topical emulsion and its vehicle control on the skin response to UV exposure” Skin Pharmaco Physiol 2005; 18; 288-293

21.  MJ Choi and HI Maibach “Elastic vesicles as transdermal drug delivery systems, Int J Cosmetic Sci, 2005, 27: 1-11.

22.  MJ Choi and HI Maibach “Liposomes/niosomes as a drug delivery system” Skin Pharmacol Physiol, 2005, 18; 209-219.

23.  MJ Choi and HI Maibach “Ceramides in healthy and diseased skin” Cosmetics & Toiletries, 2006, 121(4): 24-29..

24.  M.J. Choi, J.H. Kim and H.I. Maibach. “Topical vaccination with lipid-based DNA complex” Current Drug Delivery, 2006, 3(1); 37-45.

25.  S.H. Oh, M.J. Choi, B.I. Kim, K.M. Kim and K.N. Kim. “Antibacterial effect of oral rinses containing phytosphingosine” Key Engineering Materials 2007, Vols 342-343, 941-944.


 Presentation:

1.    M. J. Choi, and H. Kim. "PH-sensitive liposomes consisted of polymeric phosphatidylethanolamine and fatty acids", 65th Annual Meeting of the Korea Chemical Society, (1990).

2.    M. J. Choi and H. Kim. “PH-sensitive polymeric liposomes consisted of phosphatidylethanolamine and fatty acids", presented at the Fall Meeting of the Korean Biochemical Society, (1990).

3.    M. J. Choi and H. Kim. "Novel targeting liposomes: Temperature and pH        -sensitive liposomes (I)", presented at the Spring Meeting of the Korean Biochemical Society, (1992).

4.    M. J. Choi, et al. "Novel targeting liposomes: Temperature and pH- sensitive liposomes (II)", presented at the fall conference on Biochemistry and Molecular Biology, (1993).

5.    J. S. Chang, M. J. Choi, et al.  "Targeting of galactocerebroside inserted liposomes to liver cell", presented at the fall conference on Biochemistry and Molecular Biology, (1993).

6.    S. Y. Cho, M. J. Choi, et al. "Binding assay system of CTL epitope peptides”, at the Spring Meeting of the Korean Biochemical Society, (1994).

7.    M. J. Choi et al. " Interaction of HIV-V3 peptides with liposomes (I)", presented at the Spring Meeting of the Korean Biochemical Society, (1994)

8.    M. J. Choi et al. " Interaction of HIV-V3 peptides with liposomes (II) ", presented at the Fall Meeting of the Korean Biochemical Society, (1994).

9.    S. W. Chi, M. J. Choi, et al. " 2D-NMR studies on the function and nonfunctional signal sequences of E. coli ribose binding protein ", presented at the Fall Meeting of the Korean Biochemical Society, (1994).

10.  M. J. Choi et al. "Immunogenicity of synthetic HIV-V3 loop peptides I : Humoral  immunity ", 6th Annual Meeting of the Korean Society for Molecular Biology, (1994).

11.  J. S. Chang, M. J. Choi, et al. " Immunogenicity of synthetic HIV-V3 loop peptides II : Cellular immunity", 6th Annual Meeting of the Korean Society for Molecular Biology, (1994).

12.  K. Y. Lee, M. J. Choi, et al. "Confirmation of N-protein peptide specific CTL from live Hantaan virus immunized mice", 30th Spring Meeting of the Korean Society for Immunology, (1995).

13.  T. Y. Kim, M. J. Choi, et al. "Generation of peptide specific CTL in immunized mice with Hantaan N-protein peptide encapsulated liposomes", 30th Spring Meeting of the Korean Society for Immunology, (1995).

14.  J. S. Chang, M. J. Choi, et al. "Generation of HIV loop specific humoral and cellular immunity", 30th Spring Meeting of the Korean Society for Immunology, (1995).

15.  M. J. Choi, et al. "Interaction of tenesin fragment peptide with liposomes (I)", presented at the Fall Meeting of the Korean Biochemical Society, (1995).

16.  M. J. Choi, et al. "Interaction of tenesin fragment peptide with liposomes (II)", presented at the Fall Meeting of the Korean Biochemical Society, (1995).

17.  L. Luo, M J. Choi, et al. "Induction of HIV-specific Cytotoxic T cell response by HIV Gag particle carrying immunodominant multiple V3 loop of GP120", presented at the American Society for Virology, (1996).

18.  M. J. Choi, et al. “Interaction of tenecin fragments with liposomes”. Presented at the Summer Meeting of the Korean Biophysical Society, (1996).

19.  S. Ghosh, R. Wester, M.J. Choi, S. Barbadillo, X. Hui, and H. Maibach. “Comparative study of in vitro cutaneous disposition of topical caffeine formulations in human skin: Enhanced penetration using novel liposomal caffeine formulation” American Academic Dermatology, 61st Annual Meeting, March 21-26, 2003

20.  Honbo Zhai, M.J. Choi and H.I. Maibach. “Antioxidative capacity of a topical emulsion versus its vehicle” 5th Las Vegas Dermatology Seminar, November 11-14, 2004

21.  S.H. Oh, S.H. Kim, M.J. Choi, K.M. Kim and K.N. Kim. “The antibacterial effect of oral rinses containing phytosphingosine” 아시아 예방치과학회, 2004. 12

22.  S.H. Oh, M.J. Choi, B.I. Kim, K.M. Kim and K.N. Kim. “Antibacterial effect of oral rinses containing phytosphingosine” 7th Asian Symposium on Biomedical Materials, Jeju-do, Korea, August 20-23, 2006.

23.  K.N Kim, M.J. Choi and J.H. Kim. “Production of the useful materials from liquid fermentation of soybean hull by Bacillus sp” 24th IFSCC Congress Osaka Japan, October 16-19, 2006


 Books:

1.   Development and Prospects of Immunotherapetics, 2001, Korea Patent Association

2.   Dermatotoxicology 6th and 7th edition, “Tape stripping method and stratum corneum”

3.   Percutaneous Absorption 4th edition, “Percutaneous penetration of oligonucleotide drugs”. “Topical vaccination of DNA antigens: topical delivery of DNA antigens” “Effect of tape stripping on the percutaneous absorption and topical vaccination”

4.   2006년도 산업 기술 동향 분석: 난치성 피부질환 치료제, 산업기술평가원

5.   Handbook of Cosmetic science and Technology 2nd edition, “Ceramides in barrier function of healthy and diseased skin” “Role of ceramides in skin stress: UV, tape stripping and crowding” in press

6.   Cosmeceuticals 2nd edition, “Liposomes/niosomes as a topical drug delivery system” in press


 Patents:

Patent Title

Filing No

Date of Filing

Nation

Process for preparation of liver targeting pH-sensitive liposomes

115418

1997.5.20

Korea

Process for preparation of stability improved pH-sensitive liposomes

115419

1997.5.20

Korea

Process for preparation of temperature and pH sensitive liposomes

115420

1997. 5.20

Korea

Human immunomodulating CTL peptides against a HCV (I)

137153

1998.2.4

Korea

Human immunomodulating CTL peptides against a HBV

137617

1998. 2.10

Korea

Preparation of pH-sensitive liposomes containing of immunodominant HIV peptides

154576

1998.7.10

Korea

Human immunomodulating CTL peptides against a Hantaan virus

166425

1998.9.23

Korea

PH-Sensitive liposomes containing of multivalent CTL polypeptides derived from various virus origin

173364

1998.10.29

Korea

PH-sensitive liposomes containing of HCV human CTL epitope peptides

173365

1998.10.29

Korea

PH-Sensitive liposomes containing of HBV human CTL epitope peptides

173366

1998.10.29

Korea

PH-Sensitive liposomes containing of Hantaan virus human CTL epitope peptides

178422

1998.11.23

Korea

PH-sensitive liposomes containing of human CTL epitope peptide derived from HBV X-protein

189701

1999.1.18

Korea

Human immunomodulating CTL peptides against a HCV (II)

190910

1999.1.21

Korea

Human immunomodulating CTL peptides derived from HBV X protein

194283

1999.2.8

Korea

Liposomes comprising peptide antigens derived from X-protein of HBV

00010

 

PCT/KR98

Liposomes containing of protein antigens derived from H,pylori

207289

1994.4.12

Korea

Assay system for antibiotics using liposomes

 

1999.4.9

Korea

항암활성을 지닌 파이토스핑고신 유도체

 

 

국제특허

7-디하이드로콜레스테롤 사이클로덱스트린의 포접복합체, 이를 포함하는 화장료 조성물 7-디하이드로콜레스테롤의 안정화 방법

0473716

2005. 2.18

Korea

피부 미백 주름 개선용 활성 추출물 제조 방법

0074716

2005. 7. 19

Korea

피부보호용 디이노코커스 라디오두란스 세포막 추출물 이를 포함하는 피부 외용제

0002585

2006. 1. 12

Korea

복분자 발효물을 이용한  피부 질환 치료용 조성물

등록

 

Korea

탈모의 예방, 치료 또는 육모용 조성물

등록

1003532

Korea

국소투여용 나노에멀젼

출원

2008

Korea

트리메칠피토스핑고신 유도체를 함유한 건선 예방 치료용 조성물

출원

2008

Korea

Composition for the prevention and treatment of alopecia or for hair growth

출원

2009

PCT/KR2009/004254

 



 

티스토리 툴바